Q7W2N9 Acetylornithine aminotransferase 2 MolNFT, Molecular NFT on GenesisL1

Acetylornithine aminotransferase 2

MOLNFT AF v1 smart contract in GenesisL1 blockchain:

0xBf7491af3407816DFa88a5EA4c82e8A2B1D721eD

IPFS of NFT metadata:

bafybeib5y3gqh3osd443f7xwffcdoi2o67rt6q2ttfsqrxmol2qaonyacm/metadata.json

IPFS of structure file:

bafybeiajpngjb325hm5ysj7zcucvomjz2pn4awt7x4lyu2vjusyugwvowe/AF-Q7W2N9-F1-model_v2.pdb

First NFT owner address (eip-55):

0xddD89F6cedc3679f21663f3046B4aB3D5161E34E

First NFT owner address (bech32):

genesis1mhvf7m8dcdne7gtx8ucydd9t84gkrc6whvv4gj

Current NFT ID #21732 owner (web3):

First owner GALLERY | EVM EXPLORER | COSMOS EXPLORER

MOLNFT AF v1

NFT id:
21732
Accession (UniProt):
Q7W2N9
Name::
Acetylornithine aminotransferase 2
Experimental Method:
Predicted structure
Sequence source:
BORDETELLA PARAPERTUSSIS (STRAIN 12822 / ATCC BAA-587 / NCTC 13253)

NFT data

MolNFT AF v1 is an AlphaFold database of AI predicted Swiss-Prot protein sequences preserved as regular ERC-721 NFT tokens on GenesisL1 blockchain for public free use, research and entertainment:

https://alphafold.ebi.ac.uk/
Jumper, J., Evans, R., Pritzel, A. et al. Highly accurate protein structure prediction with AlphaFold. 
Nature 596, 583–589 (2021). https://doi.org/10.1038/s41586-021-03819-2

MOLNFT Q7W2N9 research and analysis (ICN3D with VR)

FASTA sequences

>sp|Q7W2N9|ARGD2_BORPA Acetylornithine aminotransferase 2 OS=Bordetella parapertussis (strain 12822 / ATCC BAA-587 / NCTC 13253) OX=257311 GN=argD2 PE=3 SV=1 MEFSQFKVNALMEITACPDLVFVRGQGSWLEDHAGKRYLDFVQGWAVNTLGHCAPEMKRALAEQADKLMNPSPAFYNLPSIELAQRLTSASCFDRVFFANSGAEANEGAIKLARKWGRVNRNGAYKIITMNHGFHGRTLATMSASGKPGWDTMFAPQVEGFPKAEINDLDSVRALIDAQTVAVMLEPVQGEAGVIPATREFMQGLRKLADEHGILFIVDEVQTGMGRTGSLFAYQQFDVIPDIMTLAKGIGGGIPLAALLAREEVCVFAHGDQGGTYNGNPLCAAVGVAVFDTITAPGFMEAAQARTRQLSEGLLALSAKRGLRGERGMGLLRALVLDRDDAPAIVEAARMLAPEGLLLNAPRGNLLRFMPALNVTEADMARMLEQLDGVIAAVRK

Q7W2N9 AF NFT

MOLNFT AF v1

NFT data

MOLNFT Q7W2N9 research and analysis (ICN3D with VR)

FASTA sequences

We use cookies on this site to enhance your user experience